Department of Ophthalmology, Otolaryngology & Dermatology, College of Korean Medicine, Dongshin University, Naju-si, Republic of Korea.
Medicine (Baltimore). 2022 Nov 25;101(47):e31468. doi: 10.1097/MD.0000000000031468.
The prevalence of dry eye, which is a common lacrimal disease, is steadily increasing in modern society. However, fundamental treatment for it has not yet been established. This study aims to assess the efficacy and safety of a novel medical device, the biodegradable microneedle acupuncture (BMA), using a traditional intradermal acupuncture needle as the control acupuncture for dry eye.
This study will be an investigator-initiated, assessor-blinded, comparative, superiority pilot randomized controlled trial. A total of 30 patients with dry eye will be randomly assigned to the experimental or the control group in equal proportion. For the experimental group, the BMA will be applied to both sides of 5 acupoints including BL2, GB14, TE23, EX-HN5, and ST1. For the control group, conventional intradermal acupuncture will be applied to the same acupoints. The needles will be attached for 4 hours. Over 4 weeks, both the interventions will be performed 12 times in total. The primary outcome would be the ocular surface disease index. The secondary outcomes would be the visual analog scale for subjective symptoms, quality of life, Schirmer I test, and general assessment.
The findings of this study on the efficacy and safety of the BMA would be helpful for patients with dry eye in clinical practice. Further, these results would provide for the foundation of a large-scale BMA study.
干眼症是一种常见的泪液疾病,其患病率在现代社会中稳步上升。然而,其根本治疗方法尚未确立。本研究旨在评估一种新型医疗器械——生物可降解微针针灸(BMA)的疗效和安全性,以传统皮内针灸针作为对照针灸治疗干眼症。
本研究将是一项由研究者发起、评估者设盲、比较、优效性的前瞻性随机对照试验。共 30 名干眼症患者将按比例随机分为实验组和对照组。实验组将在 BL2、GB14、TE23、EX-HN5 和 ST1 这 5 个穴位的两侧应用 BMA。对照组将在相同的穴位应用传统皮内针灸。针将保留 4 小时。在 4 周内,两种干预措施共进行 12 次。主要结局指标为眼表疾病指数。次要结局指标为主观症状视觉模拟量表、生活质量、泪液分泌试验和总体评估。
本研究关于 BMA 疗效和安全性的发现将有助于临床实践中干眼症患者。此外,这些结果将为 BMA 的大规模研究提供基础。